Carbon Biosciences
Michael Rak has a long and varied work experience. Michael began their career in 2004 as a Diagnostic Technician at LabCorp Diagnostic Laboratories. In 2005, they moved to Duke University as a Research Technician at the Human Vaccine Institute. In 2007, they started as a PhD student at the University of Arizona, where they also served as a Research Specialist and Lab Manager in the Goodrum Lab. In 2018, they joined Boston College as a Postdoctoral Researcher in the Altindis Lab. From 2019 to 2021, they worked at Renascent Biosciences as a Research Scientist. Finally, in 2021, they joined Rubius Therapeutics as a Senior Scientist and Scientist, and in 2023 they moved to Carbon Biosciences as a Senior Scientist.
Michael Rak attended the University of Maryland from 2000-2004, where they earned a BS in Biology. Michael then attended the University of Arizona from 2012-2018, where they earned a Doctor of Philosophy - PhD in Cellular and Molecular Medicine.
Carbon Biosciences
1 followers
Carbon Biosciences is expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose. Founded by Longwood Fund and gene therapy pioneers John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D., Carbon is expanding the gene therapy toolbox for the treatment of the world’s most devastating and difficult to treat diseases.